Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics by Sarah Moniz | Aug 15, 2018
T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation by Sarah Moniz | Aug 15, 2018
Building Better Biotherapeutics and Vaccines by Design: EpiVax, Inc., an Immunology Company by Adam | Oct 22, 2016Rhode Island Medical Journal, February 2013. rimed.org/rimedicaljournal/2013-02/2013-02-19-bio-epivax.pdf
Highly Immunogenic Vaccine For Prevention and Therapy of Malignant Mesothelioma by Adam | Oct 21, 2016